Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.

Affiliation

Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China. Electronic address: [Email]

Abstract

This study aimed to evaluate the cost-effectiveness of osimertinib with gefitinib or erlotinib as first-line and sequential therapy for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) in China.

Keywords

NSCLC,cost-effectiveness,first-line treatment,osimertinib,